Icos competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

John 'Chip' Scarlett is a Co-Founder at Covance and Board Member at CYTOMX THERAPEUTICS, INC. and is based in Menlo Park, California. He has worked as Board Member at GERON CORP, Board Member at Chiasma Inc, and Adjunct Assistant Professor of Medicine at Hospital of the University of Pennsylvania. John works or has worked as Various Positions at Mcneil Pharmaceuticals and Dir:Medical Research & Svcs at Mcneil Pharmaceuticals. He studied at University of Colorado Boulder between 1980 and 1982, University of Chicago - The Pritzker School of Medicine between 1973 and 1977, and Earlham College between 1969 and 1973.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Joe Turgeon is a President, COO at SPECTRUM PHARMACEUTICALS INC.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

A co-founder of CBLPath via the CBL acquisition, Carlos Urmacher is certified by the American Board of Pathology in Surgical Pathology and Dermatopathology. He is a member of the U.S. and Canadian Academy of Pathology, a member of the College of American Pathologists, and a fellow of the American Society of Clinical Pathologists. Dr. Urmacher has served as a member of the Board of Trustees and Treasurer of the New York Pathological Society, as a member of the Scientific Advisory Board of the World Health Organization and as a member of the editorial boards of The American Journal of Surgical Pathology and The American Journal of Dermatopathology. Prior to joining CBL in 2000 as Co-Director and Chief of Surgical Pathology, Dr. Urmacher served as Attending Pathologist at North Shore University Hospital – NYU School of Medicine in Manhasset, New York for nine years and as Attending Pathologist at Memorial Sloan-Kettering Cancer Center and Associate Professor of Pathology at Cornell University Medical Center for 13 years. Dr. Urmacher is a frequent lecturer and has authored more than 70 articles and six medical textbook chapters. He graduated with an M.D. degree from the Central University of Venezuela and served as Chief Resident in Pathology at Mount Sinai Hospital, New York and as Chief Fellow in Pathology at Memorial Sloan-Kettering Cancer Center and New York University Hospital. Dr. Urmacher was recently giving the honor of distinguished visitor professor in Pathology by Johns Hopkins.